Sangart Initiates Phase IIa Study Of MP4OX

Sangart has initiated dose-finding study designed to evaluate the safety and efficacy of MP4OX treatment, plus standard of care, in severely injured trauma patients with lactic acidosis due to hemorrhagic shock. MP4OX is an oxygen therapeutic agent that is designed to provide rapid oxygen delivery to ischemic tissues.

The company said that the clinical trial will be a multi-center, randomised, double-blind, controlled study that will enroll up to 75 patients who have suffered hemorrhagic shock with lactic acidosis across approximately 12 trial sites in Europe and South Africa. The primary objective of the study is to measure reduction in lactate levels after infusion of MP4OX.

According to the Centers for Disease Control and Prevention (CDC), unintentional injury kills more people between the ages of one and 44 than any other disease or illness.

Sangart’s product platform is based on the MP4 molecule, an investigational biopharmaceutical product designed to enhance the perfusion of oxygen-deprived (ischemic) tissues, and provide targeted oxygen delivery in the capillaries.

Using a pegylation approach, Sangart produces the MP4 molecule designed at the optimal oxygen affinity, diffusion potential and molecular size to perfuse capillaries and target oxygen delivery to tissues specifically at risk of ischemia.

Brian O’Callaghan, president and chief executive officer of Sangart, said: “The initiation of this study is another key milestone for Sangart as we continue to develop medicines designed to enhance the delivery of oxygen to tissues and organs that are oxygen deprived, particularly in patients who experience an acute traumatic injury.

“MP4OX is an integral part of our platform of products designed to help patients with medical conditions that deprive tissue of necessary oxygen.”